Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | PNLIP | P16233 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229403 | 0.89 | PKM (0.40) | PKMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4233195 | 0.89 | PKM (0.48) | PKMNPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL4231850 | 0.82 | PKM (0.48) | PKMESRRAPNLIPNPC1RAB9A | |
| SCHEMBL4240971 | 0.81 | HTR2A (0.40) | ESRRAPNLIP | |
| SCHEMBL4240850 | 0.79 | PKM (0.53) | PKMPNLIPMAPTF7GCGR | |
| SCHEMBL4688990 | 0.78 | PKM (0.50) | PKMESRRAPNLIPNPC1RAB9A | |
| SCHEMBL4227148 | 0.76 | PKM (0.49) | PKMNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4242192 | 0.76 | PDE7A (0.52) | PKMRAB9ASMN1; SMN2MAPT | |
| SCHEMBL4233830 | 0.75 | PKM (0.45) | PKMTAS1R3TAS1R1 | |
| SCHEMBL4236606 | 0.75 | PKM (0.56) | PKMESRRAPNLIPMAPTGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PKM 1734/4885ESRRA 1441/4885PNLIP 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.